- CA$3.48m
- CA$7.65m
Annual balance sheet for Hemostemix, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 0.024 | 0.258 | 0.219 | 0.136 | 0.155 |
| Net Total Receivables | 0.076 | 2.06 | 0.343 | 0.139 | 0.025 |
| Prepaid Expenses | |||||
| Total Current Assets | 0.1 | 2.32 | 0.562 | 0.465 | 0.314 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.004 | 0.002 | 0.001 | 0 | 0 |
| Net Intangible Assets | |||||
| Total Assets | 0.104 | 2.32 | 0.563 | 0.465 | 0.314 |
| Payable / Accrued | |||||
| Notes Payable / Short Term Debt | |||||
| Total Current Liabilities | 4.15 | 3.42 | 4.37 | 2.62 | 2.88 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Liabilities | 4.15 | 3.42 | 5.85 | 7.23 | 7.68 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | -4.05 | -1.1 | -5.28 | -6.77 | -7.37 |
| Total Liabilities & Shareholders' Equity | 0.104 | 2.32 | 0.563 | 0.465 | 0.314 |
| Total Common Shares Outstanding |